ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. Purchases 437,600 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. bought 437,600 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was acquired at an average cost of $9.06 per share, with a total value of $3,964,656.00. Following the completion of the purchase, the director now owns 8,994,374 shares of the company’s stock, valued at approximately $81,489,028.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, March 27th, Ra Capital Management, L.P. acquired 505,954 shares of ARS Pharmaceuticals stock. The stock was bought at an average cost of $9.79 per share, with a total value of $4,953,289.66.

ARS Pharmaceuticals Stock Down 0.4 %

Shares of SPRY stock opened at $9.96 on Thursday. The firm’s 50 day moving average price is $7.75 and its two-hundred day moving average price is $5.80. ARS Pharmaceuticals, Inc. has a fifty-two week low of $2.55 and a fifty-two week high of $10.20. The stock has a market cap of $961.14 million, a price-to-earnings ratio of -17.47 and a beta of 0.78.

Analyst Upgrades and Downgrades

SPRY has been the subject of several analyst reports. Leerink Partnrs raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $6.00 to $18.00 in a report on Tuesday, March 5th. Wedbush reissued an “outperform” rating and set a $19.00 price objective on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Finally, William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 20th.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its stake in ARS Pharmaceuticals by 22,300.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after buying an additional 5,575 shares in the last quarter. AJOVista LLC purchased a new stake in ARS Pharmaceuticals during the fourth quarter valued at about $43,000. Tower Research Capital LLC TRC purchased a new stake in ARS Pharmaceuticals during the second quarter valued at about $64,000. Wells Fargo & Company MN acquired a new position in shares of ARS Pharmaceuticals in the 2nd quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after purchasing an additional 8,652 shares during the period. 68.16% of the stock is owned by institutional investors and hedge funds.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.